Tianda Pharmaceuticals (SEHK:455) - Aandelenkoers, Nieuws & Analyse

455 Overzicht aandelen

455 fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Risicoanalyse

De winst is de afgelopen 5 jaar met 41.5% per jaar gedaald

Heeft geen betekenisvolle marktkapitalisatie ( HK$398M )

Tianda Pharmaceuticals Limited Concurrenten

Modern Chinese Medicine Group

SEHK:1643

HK$249.0m

Wai Yuen Tong Medicine Holdings

SEHK:897

HK$236.3m

Lee's Pharmaceutical Holdings

SEHK:950

HK$718.4m

PuraPharm

SEHK:1498

HK$252.8m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Tianda Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	HK$0.18
52 Week Hoogtepunt	HK$0.28
52 Week Laag	HK$0.16
Bèta	0.077
11 maand verandering	-2.12%
3 maanden verandering	-22.92%
1 Jaar Verandering	-18.14%
33 jaar verandering	-36.21%
5 jaar verandering	9.47%
Verandering sinds IPO	-68.38%

Recent nieuws en updates

Lacklustre Performance Is Driving Tianda Pharmaceuticals Limited's (HKG:455) 25% Price Drop

Oct 28

Recent updates

Lacklustre Performance Is Driving Tianda Pharmaceuticals Limited's (HKG:455) 25% Price Drop

Oct 28

Tianda Pharmaceuticals Limited (HKG:455) Investors Are Less Pessimistic Than Expected

Aug 16

Is Tianda Pharmaceuticals (HKG:455) Using Debt In A Risky Way?

Jun 20

There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump

Mar 27

Rendement voor aandeelhouders

	455	HK Pharmaceuticals	HK Markt
7D	-6.1%	0.07%	-0.6%
1Y	-18.1%	-10.2%	9.6%

Rendement versus industrie: 455 presteerde slechter dan de Hong Kong Pharmaceuticals -sector, die het afgelopen jaar een rendement van -10.2 % opleverde.

Rendement versus markt: 455 presteerde slechter dan Hong Kong Market, dat het afgelopen jaar een rendement van 9.6 % opleverde.

Prijsvolatiliteit

Is 455's price volatile compared to industry and market?
455 volatility
455 Average Weekly Movement	6.5%
Pharmaceuticals Industry Average Movement	6.8%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	19.2%
10% least volatile stocks in HK Market	4.3%

Stabiele aandelenkoers: 455 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van 455 is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1992	695	Alan Fang	www.tiandapharma.com

Tianda Pharmaceuticals Limited houdt zich, samen met haar dochterondernemingen, bezig met onderzoek en ontwikkeling, productie en verkoop van farmaceutische, biotechnologische en gezondheidsproducten op het Chinese vasteland, in Hongkong en Australië. Het bedrijf levert Chinese geneesmiddelen, chemische medicijnen, biologische en gezondheidsproducten en medische apparatuur op het gebied van cardio-cerebrovasculaire, pediatrische, antigriep- en luchtwegaandoeningen, infectiebestrijding, ontgifting, kankerbestrijding en andere therapieën. Het bedrijf biedt zijn gezondheidsproducten aan onder de merknamen Herb Valley en Tuokang.

Tianda Pharmaceuticals Limited Samenvatting

Hoe verhouden de winst en inkomsten van Tianda Pharmaceuticals zich tot de beurswaarde?
455 fundamentele statistieken
Marktkapitalisatie	HK$397.76m
Inkomsten(TTM)	-HK$47.26m
Inkomsten(TTM)	HK$384.68m

1.0x

P/S-verhouding

-8.4x

Koers/Winstverhouding

Is 455 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
455 resultatenrekening (TTM)
Inkomsten	HK$384.68m
Kosten van inkomsten	HK$208.40m
Brutowinst	HK$176.28m
Overige uitgaven	HK$223.54m
Inkomsten	-HK$47.26m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.022
Brutomarge	45.83%
Nettowinstmarge	-12.29%
Schuld/Eigen Vermogen Verhouding	16.9%

Hoe presteerde 455 op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

1.4%

Huidig dividendrendement

-12%

Uitbetalingsratio

455 Overzicht aandelen

Risicoanalyse

Tianda Pharmaceuticals Limited Concurrenten

SEHK:1643

HK$249.0m

SEHK:897

HK$236.3m

SEHK:950

HK$718.4m

SEHK:1498

HK$252.8m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Lacklustre Performance Is Driving Tianda Pharmaceuticals Limited's (HKG:455) 25% Price Drop

First half 2024 earnings released

New major risk - Financial data availability

New major risk - Financial position

New minor risk - Share price stability

Tianda Pharmaceuticals Limited Provides Unaudited Consolidated Earnings Guidance for the Six-Month Period from 1 January 2024 to 30 June 2024

Recent updates

Lacklustre Performance Is Driving Tianda Pharmaceuticals Limited's (HKG:455) 25% Price Drop

First half 2024 earnings released

New major risk - Financial data availability

New major risk - Financial position

New minor risk - Share price stability

Tianda Pharmaceuticals Limited Provides Unaudited Consolidated Earnings Guidance for the Six-Month Period from 1 January 2024 to 30 June 2024

Tianda Pharmaceuticals Limited (HKG:455) Investors Are Less Pessimistic Than Expected

Tianda Pharmaceuticals Limited to Report First Half, 2024 Results on Aug 28, 2024

Is Tianda Pharmaceuticals (HKG:455) Using Debt In A Risky Way?

Tianda Pharmaceutical Technology (Zhuhai) Co., Ltd. Receives Drug Registration Approval of Ibuprofen Suspension

Tianda Pharmaceuticals Limited Approves Final Dividend

Now 24% overvalued after recent price rise

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 07, 2024

Now 21% overvalued after recent price rise

There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump

New major risk - Revenue and earnings growth

Tianda Pharmaceuticals Limited Proposes Final Dividend for the Year Ended 31 December 2023

Tianda Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

New minor risk - Share price stability

Now 26% undervalued

Estimating The Fair Value Of Tianda Pharmaceuticals Limited (HKG:455)

Now 29% undervalued

Tianda Pharmaceuticals Limited Announces Executive Changes, Effective 29 August 2023

Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Interim Period Ended June 30, 2023

Tianda Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Now 28% undervalued

Tianda Pharmaceuticals Limited (SEHK:455) entered into an equity transfer agreement to acquire 45% stake in Yunnan Mengsheng Pharmaceutical Co., Ltd from Yunnan Linuo Biotechnology Co., Ltd. for HKD 23.5 million.

Tianda Pharmaceuticals Limited Announces Board Changes

Now 25% undervalued after recent price drop

Is Tianda Pharmaceuticals (HKG:455) Using Debt Sensibly?

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 27, 2023

Full year 2022 earnings released: HK$0.025 loss per share (vs HK$0.011 loss in FY 2021)

Executive Chairman & MD recently bought HK$2.7m worth of stock

Executive Chairman & MD recently bought HK$448k worth of stock

Executive Chairman & MD recently bought HK$52k worth of stock

Tianda Pharmaceuticals (HKG:455) Has Debt But No Earnings; Should You Worry?

First half 2023 earnings released: HK$0.008 loss per share (vs HK$0.008 loss in 1H 2022)

Tianda Pharmaceuticals Limited to Report First Half, 2023 Results on Nov 25, 2022

Less than half of directors are independent

Executive Chairman & MD recently bought HK$129k worth of stock

Tianda Pharmaceuticals Limited Declares Final Dividend

Tianda Pharmaceuticals Limited, Annual General Meeting, Aug 25, 2022

Tianda Pharmaceuticals Limited Proposes Final Dividend for the Year Ended March 31, 2022, Payable on September 08, 2022

Full year 2022 earnings released

Tianda Pharmaceuticals Limited Proposes Special Dividend for the Year Ended 31 March 2022

Tianda Pharmaceuticals Limited to Report Fiscal Year 2022 Results on Jun 29, 2022

Less than half of directors are independent

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Non-Executive Director Lee George Lam has left the company

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Full year 2021 earnings released: HK$0.013 loss per share (vs HK$0.001 profit in FY 2020)

Full year 2021 earnings released: HK$0.013 loss per share (vs HK$0.001 profit in FY 2020)

Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Year Ended 31 March 2021

First half 2021 earnings released: HK$0.007 loss per share

Is Tianda Pharmaceuticals (HKG:455) Using Too Much Debt?

First half 2021 earnings released: HK$0.007 loss per share

Tianda Pharmaceuticals Limited to Report First Half, 2021 Results on Nov 27, 2020

Rendement voor aandeelhouders

Prijsvolatiliteit